Show Summary Details
Page of

Hybrid Therapies 

Hybrid Therapies
Hybrid Therapies

Claudio Ronco

, Silvia De Rosa

, and Sara Samoni

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 June 2021

General features of hybrid therapies include: 1) use of standard equipment from ESRD programs, including machinery, filters, extracorporeal blood circuitry, and on-line fluid production for dialysate and ultrafiltrate replacement; 2) therapy is intentionally “discontinuous” (i.e. intended duration is less than 24 hrs); 3) treatment duration is longer than conventional IHD. Solute and fluid removal are slower than conventional IHD, but faster than conventional CRRT, thereby allowing “scheduled down time” without compromise in total daily dialysis dose. Solute removal is largely diffusive, but variants with a convective component, such as SLEDD-f and AVVH, are possible.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.